الفهرس Only 14 pages are availabe for public view
 |  | from | 167 |  |  |
| | | from | 167 | | |
Abstract
Cerebrovascular disease is one of the most common diseases. In the united states, annual stroke incidence has increased from 500,000 new cases to more than 750.000. (Dressman et al., 2002). Meanwhile, Abdul Ghani revealed that the annual incidence of stroke in Egypt is about 2.1 per one thousand per year (Abdul-Ghani, 1994)
Until recently, there was no effective therapy or management strategy to reduce stroke mortality and/or disability (Cornu et al., 2000).
Efforts have been devoted to developing treatments for stroke end at restoring cerebral perfusion (thrombolysis) or at limiting neural damage (neuroprotection), fortunately, some progress has been made. (Cornu et al., 2000).
Munoz-Torrero et al, reported that although one of the therapeutic strategies in the acute phase of cerebral ischaemia is the use of antiaggregants and anticoagulants. Until recently, their clinical use was empirical. It was based on the favourable results of clinical trials using these drugs in cerebral ischaemia and the results of some preliminary clinical trials (although not the definitive trials) in the acute phase of cerebral infarct. These involved a small number of patients and randomization errors which did not definitely show the benefit/risk ratio, particularly in cases of bleeding of any origin. However, they served as a basis for further studies (Munoz-Torrero et al., 1999)